Citations

Clear

959 citation(s) found for "Service, F J".

Implementation of a virtual community of practice to promote the empowerment of middle-aged people with multimorbidity: study protocol of a randomised controlled trial
Campillejo, Alba , Larrondo, Ileana Gefaell , Ramos‐García, Vanesa , Koatz, Débora , Santos-Álvarez, Anthea, Barrio-Cortés, Jaime , Gómez-Rueda, Sara, Calderón‐Larrañaga, Amaia , Garrido-Elustondo, Sofía, León, Beatriz González de , Ramón-Vazquez, José, Martín, Candelaria , Súarez-Fernández, Carmen, Parra-Caballero, Pedro, Quiroga-Colina, Patricia, Ramírez‐Puerta, Ana Belén, Tello-Bernabé, María-Eugenia, Sanchez-Gamborino, Estrella, Ugalde-Abiega, Beatriz, Vall‐Roqué, Helena , Abt-Sacks, Analía , Hernández-Yumar, Aránzazu , Muth, Christiane , Akker, Marjan van den , Orrego, Carola , González‐González, Ana Isabel , van den Akker, Marjan , Orrego, Carola , González-González, Ana Isabel , García, Alba Campillejo , Cifuentes, Patricia, Coello, Santiago Domínguez , García-García, Francisco Javier, Parra, Pedro , Vicente‐Rabaneda, Esther F. , Ruíz-López, Marta, Tello-Bernabé, María Eugenia, Ugalde-Abiega, Beatriz , Duarte‐Díaz, Andrea , Sacks, Analía Abt , Torres‐Castaño, Alezandra , Álvarez‐Pérez, Yolanda , Montori, Víctor M. , Perestelo‐Pérez, Lilisbeth

Mayo Clinic

BMJ Open | May 24, 2024 | Volume: 14 | Issue: 5 | Pages: e084937

10.1136/bmjopen-2024-084937 | PMID 38803252 Get It

Introduction Empowering people living with multimorbidity (multiple chronic conditions) to gain greater confidence in managing their health can enhance their quality of life. Education focused on self-management is a key tool for fostering patient empowerment and is mostly provided on an individual basis. Virtual communities of practice (VCoP) present a unique opportunity for online education in chronic condition self-management within a social context. This research aims to evaluate the effectiveness/cost-effectiveness of individualised, online self-management education compared with VCoP among middle-aged individuals living with multiple chronic conditions. Methods and analysis People aged 30–60, living with ≥2 chronic conditions and receiving care in primary care (PC) centres and outpatient hospital-based clinics in Madrid and Canary Islands will enrol in an 18-month parallel-design, blinded (intervention assessment and data analysts), pragmatic (adhering to the intention-to-treat principle), individually randomised trial. The trial will compare two 12-month web-based educational offers of identical content; one delivered individually (control) and the other with online social interaction (VCoP, intervention). Using repeated measures mixed linear models, with the patient as random effect and allocation groups and time per group as fixed effects, we will estimate between-arm differences in the change in Patient Activation Measure from baseline to 12 months (primary endpoint), including measurements at 6-month and 18-month follow-up. Other outcomes will include measures of depression and anxiety, treatment burden, quality of life. In addition to a process evaluation of the VCoP, we will conduct an economic evaluation estimating the relative cost-effectiveness of the VCoP from the perspectives of both the National Health System and the Community. Ethics and dissemination The trial was approved by Clinical Research Ethics Committees of Gregorio Marañón University Hospital in Madrid/Nuestra Señora Candelaria University Hospital in Santa Cruz de Tenerife. The results will be disseminated through workshops, policy briefs, peer-reviewed publications and local/international conferences. Trial registration number NCT06046326 .
Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial
Magen, Daniella , Sellier-Leclerc, Anne-Laure A., Shasha‐Lavsky, Hadas , Šimková, Eva, Devresse, Arnaud , Michael, Mini , Frishberg, Yaacov, Mourani, Chebl, Saqan, Rola , Guzzo, Isabella, Makarova, Nune , Willey, Richard G., Kaspar, Cristin , Gansner, John M. , Groothoff, Jaap W. , Lieske, John C. , Sellier‐Leclerc, Anne‐Laure , Bakkaloglu, Sevcan Azime , Singer, Richard , Guzzo, Isabella

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 566-566

10.1681/asn.20233411s1566b Get It

Lumasiran for Patients With Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-Month Analysis of the Phase 3 ILLUMINATE-C Trial
Frishberg, Yaacov, Michael, Mini , Groothoff, Jaap W. , Shasha‐Lavsky, Hadas , Šimková, Eva, Sellier-Leclerc, Anne-Laure A., Devresse, Arnaud , Egziabher, Fitsum Guebre, Mourani, Chebl, Saqan, Rola , Willey, Richard G., Gansner, John M. , Magen, Daniella , Lieske, John C. , Sellier‐Leclerc, Anne‐Laure , Bakkaloglu, Sevcan Azime , Singer, Richard

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 416-416

10.1681/asn.20223311s1416a Get It

ILLUMINATE-C, a Single-Arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD Stages 3b-5, Including Those on Hemodialysis
Michael, Mini , Groothoff, Jaap W. , Shasha‐Lavsky, Hadas , Frishberg, Yaacov, Šimková, Eva, Sellier-Leclerc, Anne-Laure A., Devresse, Arnaud , Egziabher, Fitsum Guebre, Mourani, Chebl, Saqan, Rola , Willey, Richard G., Habtemarian, Bahru A., Bhan, Ishir , McGregor, Tracy L., Magen, Daniella , Lieske, John C. , Sellier‐Leclerc, Anne‐Laure , Bakkaloglu, Sevcan Azime , Singer, Richard

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: B2-B2

10.1681/asn.20213210s1b2a Get It

Cardiac biomarkers for diagnosing Takotsubo syndrome
Schweiger, Victor , Vece, Davide Di , Cammann, Victoria L. , Koleva, Iva, Würdinger, Michael , Gilhofer, Thomas , Rajman, Katja, Szawan, Konrad A. , Niederseer, David , Gili, Sebastiano , Franke, Jennifer , Meder, Benjamin , Knorr, Maike, Jansen, Thomas , Bruno, Francesco , Filippo, Ovidio De , Stefanini, Giulio , Wańha, Wojciech , Lewinski, Dirk von , Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Jacobshagen, Claudius, Karakas, Mahir , Pott, Alexander , Meyer, Philippe , Roffi, Marco , Wolfrum, Mathias , Fischer, Thomas, Vasankari, Tuija , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Poledníková, Karolína, Massoomi, Michael , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio , Ishibashi, Iwao, Himi, Toshiharu, Din, Jehangir , Rihal, Charanjit S. , Jörg, Lucas, Rickli, Hans , Böhm, Michael , Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Rottbauer, Wolfgang , Budnik, Monika , Opolski, Grzegorz , Kong, William , Dalakoti, Mayank , Imori, Yoichi , Münzel, Thomas , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Citro, Rodolfo , Vecchione, Carmine , Bossone, Eduardo , Meder, Benjamin , Bruno, Francesco , De Filippo, Ovidio , Campo, Gianluca , von Lewinski, Dirk , Tschöpe, Carsten , Pfister, Roman , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Kobza, Richard , Galiuto, Leonarda , Lairez, Olivier , Gilyarov, Mikhail , Akin, Ibrahim , Ukena, Christian , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Böhm, Michael , Widimský, Petr , Rottbauer, Wolfgang , Schunkert, Heribert , Thiele, Holger , Bauersachs, Johann , Di Mario, Carlo , Bax, Jeroen J , Templin, Christian , Koleva, Iva, Citro, Rodolfo , Vecchione, Carmine , Bossone, Eduardo , Neuhaus, Michael, Jaguszewski, Miłosz , Noutsias, Michel , D’Ascenzo, Fabrizio , Campo, Gianluca , Raposeiras‐Roubín, Sergio , Dichtl, Wolfgang , Cuneo, Alessandro , Köenig, Wolfgang , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Airaksinen, Juhani , Napp, L. Christian , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , El‐Battrawy, Ibrahim , Toušek, Petr , Winchester, David E. , Gałuszka, Jan , Ukena, Christian , Poglajen, Gregor , Kato, Ken , Al‐Shammari, Ali Saad , Prasad, Abhiram , Rihal, Charanjit S. , Liu, Kan , Schulze, Paul Christian , Bianco, Matteo , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Pieske, Burkert , Horowitz, John D. , Mario, Carlo Di , Bax, Jeroen J. , Crea, Filippo , Ruschitzka, Frank T.

Mayo Clinic

European Heart Journal | May 8, 2024 | Volume: 45 | Issue: 25 | Pages: 2254-2258

10.1093/eurheartj/ehae231 | PMID 38717630 Get It

Flash glucose monitoring for Indigenous Australians with type 2 diabetes: a randomised pilot and feasibility study
Eer, Audrey , Hearn, Tracey, Atkinson‐Briggs, Sharon , Jones, Jessica , Twigg, Stephen M. , Sinha, Ashim, O’Neal, David N. , Kelly, Ray

Mayo Clinic

No container title available | May 3, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3974235/v1 Get It

Abstract Background: Flash glucose monitoring (FGM) can improve diabetes management, but no randomised controlled trials (RCTs) of FGM have been undertaken in Indigenous Australian populations. This study aimed to assess the feasibility of performing a RCT of FGM in Indigenous Australians with type 2 diabetes. Methods: In this open-labelled pilot RCT, Indigenous adults with type 2 diabetes were randomised to FGM or standard care for 6 months. Eligible participants were being treated with injectable diabetes medications and had a glycosylated haemoglobin (HbA1c) ≥ 7.0%. The feasibility outcome was the proportion of participants completing the trial. The preliminary effective outcome was the change in HbA1c. Secondary effectiveness outcomes included a change in time spent in target blood glucose; safety (hypoglycaemic episodes); and quality of life (EuroQol 5-Dimension 3-Level (EQ-5D-3L) score). Results: Of 126 screened individuals, 74 were eligible, 40 (31.7%) were randomised and 39 (97.5%) completed the study. Participants’ baseline characteristics were similar between the FGM and usual care groups, except for sex and body mass index. There were no between-group differences for: change in HbA1c; percentage of time spent in target blood glucose, low glucose and high glucose; or EQ-5D-3L scores. No severe hypoglycaemic episodes occurred. Conclusions: This is the first pilot RCT of FGM in Indigenous Australians with type 2 diabetes. The results support a larger RCT, which is currently in progress. Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR12621000021875), retrospectively registered on 14 January 2021.
Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy
Montagna, Giacomo , Mrdutt, Mary M., Hlavin, Callie , Diego, Emilia J. , Wong, Stephanie M. , Barrio, Andrea V. , Bruele, Astrid Botty van den , Cabıoğlu, Neslihan , Sevilimedu, Varadan , Hwang, E. Shelley, Ingham, Abigail, Papassotiropoulos, Bärbel , Nguyen-Sträuli, Bich Doan , Kurzeder, Christian , Aybar, Danilo Díaz, Vorburger, Denise , Matlac, Dieter Michael, Fitzal, Florian , Meani, Francesco , Fick, Franziska, Sagasser, Jacqueline, Heil, Jörg, Dedes, Konstantin J. , Romics, László , Banys‐Paluchowski, Maggie , Müslümanoğlu, Mahmut , Pérez, María del Rosario Cueva, Díaz, Marcelo Chávez , Heidinger, Martin , Fehr, Mathias K. , Tükenmez, Mustafa , Maggi, Nadia , Ditsch, Nina , Zarhi, Sebastián Solé, Küemmel, Sherko , Bruz̆as, S., Lascio, Simona Di , Parissenti, Tamara K., Güth, Uwe , Ovalle, Valentina , Tausch, Christoph, Kuerer, Henry M. , Caudle, Abigail S. , Boileau, Jean-François , Kühn, Thorsten, Morrow, Monica , Weber, William P. , Hoskin, Tanya L. , Heidinger, Martin , Weber, Walter P , Wong, Stephanie M , Mrdutt, Mary M , Sun, Susie X. , Rosenberger, Laura H. , Matlac, Dieter Michael , Ostapenko, Edvin , Riedel, Fabian , Heil, Jörg, Karanlık, Hasan , Reinisch, Mattea , Rocco, Nicola , Gentilini, Oreste D , Paulinelli, Régis Resende , Boughey, Judy C.

Mayo Clinic

JAMA Oncology | April 25, 2024 | Volume: 10 | Issue: 6 | Pages: 793

10.1001/jamaoncol.2024.0578 | PMID 38662396 Get It

ImportanceData on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown.ObjectiveTo investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node.Design, Setting, and ParticipantsIn this multicenter retrospective cohort study that was conducted at 25 centers in 11 countries, 1144 patients with consecutive stage II to III biopsy-proven node-positive breast cancer were included between April 2013 and December 2020. The cumulative incidence rates of axillary, locoregional, and any invasive (locoregional or distant) recurrence were determined by competing risk analysis.ExposureOmission of ALND after SLNB or TAD.Main Outcomes and MeasuresThe primary end points were the 3-year and 5-year rates of any axillary recurrence. Secondary end points included locoregional recurrence, any invasive (locoregional and distant) recurrence, and the number of lymph nodes removed.ResultsA total of 1144 patients (median [IQR] age, 50 [41-59] years; 78 [6.8%] Asian, 105 [9.2%] Black, 102 [8.9%] Hispanic, and 816 [71.0%] White individuals; 666 SLNB [58.2%] and 478 TAD [41.8%]) were included. A total of 1060 patients (93%) had N1 disease, 619 (54%) had ERBB2 (formerly HER2)–positive illness, and 758 (66%) had a breast pathologic complete response. TAD patients were more likely to receive nodal radiation therapy (85% vs 78%; P = .01). The clipped node was successfully retrieved in 97% of TAD cases and 86% of SLNB cases (without localization). The mean (SD) number of sentinel lymph nodes retrieved was 3 (2) vs 4 (2) (P < .001), and the mean (SD) number of total lymph nodes removed was 3.95 (1.97) vs 4.44 (2.04) (P < .001) in the TAD and SLNB groups, respectively. The 5-year rates of any axillary, locoregional, and any invasive recurrence in the entire cohort were 1.0% (95% CI, 0.49%-2.0%), 2.7% (95% CI, 1.6%-4.1%), and 10% (95% CI, 8.3%-13%), respectively. The 3-year cumulative incidence of axillary recurrence did not differ between TAD and SLNB (0.5% vs 0.8%; P = .55).Conclusions and RelevanceThe results of this cohort study showed that axillary recurrence was rare in this setting and was not significantly lower after TAD vs SLNB. These results support omission of ALND in this population.
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Park, Han-Sol , Yin, Anna , Barranta, Caelan, Caputo, Christopher , Sachithanandham, Jaiprasath , Li, Maggie , Yoon, Steve, Sitaras, Ioannis , Jedlicka, Anne , Eby, Yolanda , Ram, Malathi , Fernández, Reinaldo E. , Baker, Owen R. , Fukuta, Yuriko , Patel, Bela , Heath, Sonya L. , Spivak, Emily S , Huamán, Moisés A. , Blair, Janis E. , Gerber, Jonathan M. , Petrini, Joann, Broderick, Patrick , Rausch, William, Cordisco, Marie Elena , Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie , Cruser, Daniel, Oei, Kevin , Abinante, Matthew, Hammitt, Laura L. , Forthal, Donald N. , Cachay, Edward R. , Marshall, Christi E., Lane, Karen , McBee, Nichol , Gawad, Amy L., Karlen, Nicky, Singh, Atika, Jabs, Douglas A. , Shade, David , Lau, Bryan , Ehrhardt, Stephan , Baksh, Sheriza , Ou, Jiangda , Na, Yu Bin , Knoll, Maria Deloria , Ornelas-Gatdula, Elysse, Gniadek, Thomas J. , Wu, Jinke, Ndahiro, Nelson , Betenbaugh, Michael J. , Ziman, Alyssa , Bloch, Evan M. , Laeyendecker, Oliver , Ziman, Alyssa , Huaman, Moises A , Laeyendecker, Oliver , Lee, John S. , Shenoy, Aarthi , Mosnaim, Giselle S , Levine, Adam C , Meisenberg, Barry R. , Anjan, Shweta , Currier, Judith S. , Paxton, James H , Sutcliffe, Catherine G , Zand, Martin S. , Raval, Jay S. , Kassaye, Seble , Yarava, Anusha , Ford, Daniel E , Appel, Lawrence J. , Shapiro, Janna R. , Arroyo‐Currás, Netzahualcóyotl , Caturegli, Patrizio , Hanley, Daniel F. , Casadevall, Arturo , Shoham, Shmuel , Gebo, Kelly A , Tobian, Aaron A.R. , Pekosz, Andrew , Klein, Sabra L , Sullivan, David

Mayo Clinic

JCI Insight | April 23, 2024 | Volume: 9 | Issue: 8 | Pages: No page available

10.1172/jci.insight.178460 | PMID 38483534 Get It

BACKGROUND COVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined. METHODS This secondary analysis correlated donor and recipient antibody levels to hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double-blind, randomized clinical trial that compared CCP to control plasma. The majority of COVID-19 CCP arm hospitalizations (15/17, 88%) occurred in this unvaccinated, seronegative subgroup. A functional cutoff to delineate recipient high versus low posttransfusion antibody levels was established by 2 methods: (i) analyzing virus neutralization–equivalent anti–Spike receptor-binding domain immunoglobulin G (anti-S-RBD IgG) responses in donors or (ii) receiver operating characteristic (ROC) curve analysis. RESULTS SARS-CoV-2 anti–S-RBD IgG antibody was volume diluted 21.3-fold into posttransfusion seronegative recipients from matched donor units. Virus-specific antibody delivered was approximately 1.2 mg. The high-antibody recipients transfused early (symptom onset within 5 days) had no hospitalizations. A CCP-recipient analysis for antibody thresholds correlated to reduced hospitalizations found a statistical significant association between early transfusion and high antibodies versus all other CCP recipients (or control plasma), with antibody cutoffs established by both methods-donor-based virus neutralization cutoffs in posttransfusion recipients (0/85 [0%] versus 15/276 [5.6%]; P = 0.03) or ROC-based cutoff (0/94 [0%] versus 15/267 [5.4%]; P = 0.01). CONCLUSION In unvaccinated, seronegative CCP recipients, early transfusion of plasma units in the upper 30% of study donors’ antibody levels reduced outpatient hospitalizations. High antibody level plasma units, given early, should be reserved for therapeutic use. TRIAL REGISTRATION ClinicalTrials.gov NCT04373460. FUNDING Department of Defense (W911QY2090012); Defense Health Agency; Bloomberg Philanthropies; the State of Maryland; NIH (3R01AI152078-01S1, U24TR001609-S3, 1K23HL151826NIH); the Mental Wellness Foundation; the Moriah Fund; Octapharma; the Healthnetwork Foundation; the Shear Family Foundation; the NorthShore Research Institute; and the Rice Foundation.
Abstract 18901: Direct Evidence that a KCNQ1 Mutation is Linked to Familial Early-onset Atrial Fibrillation
Anderson, Jeffrey , Johnson, Jonathan N. , Tester, David J. , Burgess, Don E. , Homfray, Tessa , Ackerman, Michael J. , Bartos, Daniel C. , Bastiaenen, Rachel , Gollob, Michael H. , Behr, Elijah Raphael , Guicheney, Pascale , Delisle, Brian P.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 126 | Issue: suppl_21 | Pages: No page available

10.1161/circ.126.suppl_21.a18901 Get It

KCNQ1 encodes the voltage-gated α-subunit of the I Ks channel complex (Kv7.1), and KCNQ1 mutations are associated with multiple arrhythmia syndromes. Over the past 12 years, hundreds of different KCNQ1 mutations have been linked to congenital long QT syndrome but only three KCNQ1 variants, each identified in only one family, are linked to familial early-onset AF (<50 years of age). The scant genetic linkage between KCNQ1 and early-onset AF raises the question as to whether these KCNQ1 variants actually cause familial early-onset AF or simply unmask a latent genetic predisposition. We now report that a single KCNQ1 variant, pArg231His or R231H, is identified in five unrelated families with a high penetrance of familial early-onset AF. Whole-cell patch clamp of cells heterologously expressing the obligatory I Ks β-subunit KCNE1 with wild-type KCNQ1 (WT) or WT and R231H (to mimic the patients’ genotypes) showed that cells co-expressing R231H increased current at negative and resting membrane potentials. Additionally, currents recorded from cells using a human atrial action potential (AP) waveform at physiological temperature showed that WT is minimally activated during the atrial AP and co-expression of R231H increases current measured during the atrial AP waveform by greater than 20-fold (WT, n = 10; WT & R231H, n = 12, p<0.0001). Simulations using a computational model of a human atrial AP also predicted that I Ks is normally minimally activated in the atria and R231H would dramatically increase I Ks and shorten the atrial AP. We conclude that KCNQ1 mutations are capable of causing familial early-onset AF by increasing I Ks during the atrial AP and shortening atrial refractoriness.
How do we leverage data through replication and warehousing to meet blood collection and transfusion service needs
Juskewitch, Justin E. , Briggs, Lynne, Khan, Jenna, Coyle, Terri S., Courson, Vicki L., Madde, Nageswar R., O'Leary, Mandy F., Tsang, Hamilton C. , Mathias, Patrick C , Hansen, James T, Madde, Nageswar, Tsang, Hamilton C , Juskewitch, Justin E , Hansen, James T.

Mayo Clinic

Transfusion | April 23, 2024 | Volume: 64 | Issue: 6 | Pages: 969-978

10.1111/trf.17845 | PMID 38650378 Get It

AbstractBackgroundWith the widespread adoption of Blood Establishment Computer Systems and other Blood Collection and Transfusion Service (BCTS) clinical information systems (CIS), electronic blood donor, product, and patient data are now routinely required for clinical, regulatory, operational, and quality needs. That data are often not readily accessible for such secondary use within CIS databases, particularly for applications with significant data availability requirements such as machine learning and artificial intelligence. Data replication provides one avenue by which CIS data can be made more readily available.Study Design and MethodsMembers of the AABB's Information Systems Committee along with institutional information technology colleagues provided a multi‐institutional viewpoint on data replication through the lens of BCTS specific use cases. Case studies of informatics offerings leveraging such technologies were also elicited.ResultsSix distinct use cases describe the potential role of data replication including the creation of data warehouses for frontline laboratory staff. Specific BCTS examples for each use case are presented to highlight the value of data replication, including visualization of critical inventory (O red blood cells, HLA‐compatible platelets) and utilization analytics for patient blood management. Two case studies describe the approach to implement such technologies to (1) optimize staffing via laboratory workload reporting and (2) improve access to blood via antigen‐negative blood product location services.DiscussionData replication and warehousing can empower BCTS analytic offerings not otherwise natively available through one's CIS to improve patient care and laboratory operations.